Part, Chapter, Paragraph
1 I, 2.Acr | Programme~GDP~Gross Domestic Product~HTA~Health technology assessment~
2 I, 2. 2 | to meet evolving demand. Product quality and innovation are
3 I, 2. 4 | per capita Gross Domestic Product. The data reported in Figure
4 I, 2. 4 | income and gross domestic product per capita and, particularly,
5 I, 2. 4 | Figure 2.2. Gross Domestic Product and Gross National Income
6 I, 2. 4 | rate of real gross domestic product in EUGLOREH countries.~ ~
7 I, 2. 10. 4| point-of-care scanning to match product data to patient data, verification
8 I, 2. 10. 4| assign a unique identity to a product at the point of manufacture,
9 I, 2. 10. 4| verify and authenticate a product at any point of the supply
10 I, 2. 10. 4| supplies (inventory control, product recall, etc.). For example,
11 I, 2. 10. 4| management (simplification of product identity control and quantity
12 I, 2. 10. 4| prescription process and automatic product identification in the San
13 I, 2. 10. 4| reimbursement and to check product registration. These diverging
14 I, 2. 10. 4| system for traceability, from product manufacture to patient treatment,
15 I, 2. 10. 4| increasing legal requirements for product traceability around the
16 I, 2. 10. 4| be used to identify that product in any country without any
17 II, 5. 3.Acr| Today~GDP~Gross Domestic Product~HPV~Human Papilloma Virus~
18 II, 5. 3. 1| specific Gross Domestic Product (GDP) and their trends are
19 II, 5. 3. 3| per capita Gross Domestic Product as published by EUROSTAT
20 II, 5. 5. 1| almost 1% of Gross National Product of the country (Kennelly,
21 II, 5. 5. 3| dietary factors such as animal product intake, herbal tea or tropical
22 II, 5. 6. 4| 7% of the gross national product.~ ~Future trends~ ~The impact
23 II, 5. 10. 5| than 25% of the final food product. In addition, Annex IIIa
24 II, 5. 10. 5| the EFSA for the relevant product from which they originated.~ ~ ~
25 II, 5. 11. 3| reactions from a non-conforming product is significant. The significant
26 II, 5. 15. 4| concepts of "similar medicinal product" and "clinical superiority".
27 II, 7.Acr | and Development~PROSAFE~Product Safety Enforcement Forum~
28 II, 7. 4. 5| complemented by the General Product Safety Directive (European
29 II, 7. 4. 5| accidents some kind of “product” is involved (Figure 7.23),
30 II, 7. 4. 5| countries~ ~Analyses of product or service related injuries
31 II, 7. 4. 5| injury, the nature of the product and/or service and the circumstances
32 II, 7. 4. 5| be used by regulators and product developers to ensure continuous
33 II, 7. 4. 5| Standardization (ANEC) www g, and the Product Safety Enforcement Forum (
34 II, 7. 5 | attention should be paid to product and service safety.~Set
35 II, 7. 5 | reliable information about product and service related injury
36 II, 7. 6 | safety, safety of elderly, product and service safety. Additional
37 II, 7. 7 | and the Council on general product safety (CELEX-Nr. 32001L0095).~ ~
38 III, 10. 1. 1| behavioural risk factor is the product of the complex interactions
39 III, 10. 1. 3| advertising aimed at children, product placement, and food labelling.
40 III, 10. 2. 1| Control~GDP~Gross Domestic Product~NCDs~Non-communicable diseases~
41 III, 10. 2. 1| safe or harmless tobacco product. Smokeless tobacco use,
42 III, 10. 2. 1| harmful constituents in its product, known as snus.~Health effects
43 III, 10. 2. 1| regulation of tobacco product disclosures;~· packaging
44 III, 10. 2. 1| two main sides of tobacco product packages should be mandatory
45 III, 10. 2. 1| mere description of the product without any of the messages
46 III, 10. 2. 1| provides information about a product, its effects and the industry
47 III, 10. 2. 1| market consists of various product groups such as dental floss,
48 III, 10. 2. 1| Meranwhile, in France, a product specific for young adults
49 III, 10. 2. 1| regards the composition of the product, the manufacturer, methods
50 III, 10. 2. 1| than 25% of the final food product. The amended Directive also
51 III, 10. 2. 1| UR, Riboli E (2002): Soy product consumption in 10 European
52 III, 10. 3. 2| Communities~GDP~Gross Domestic Product~HCB~Hexachlorobenzene~HCH~
53 III, 10. 3. 2| faster than gross domestic product (GDP) over the past ten
54 III, 10. 3. 2| Responsible Care, and (Global) Product stewardship. But legislation
55 III, 10. 4. 2| identify the source of the product in the country of origin.
56 III, 10. 4. 2| immediate supplier of the product and the immediate subsequent
57 III, 10. 4. 2| reported with the largest product category being nuts and
58 III, 10. 4. 2| preventative approach, such as product and process design and the
59 III, 10. 4. 2| level, applicable to any product marketed within the Community,
60 III, 10. 4. 2| and feed (6). Where a food product contains or consists of
61 III, 10. 4. 4| complemented by the General Product Safety Directive.~ ~Accidents
62 III, 10. 4. 4| accidents some kind of “product” is involved (see Figure
63 III, 10. 4. 4| the injury and that of the product and/or service, as well
64 III, 10. 4. 4| be used by regulators and product developers to ensure continuous
65 III, 10. 4. 4| Standardization (ANEC) www g, and the Product Safety Enforcement Forum (
66 III, 10. 5. 1| Alliance (2006): Child safety product guide: potentially dangerous
67 III, 10. 5. 2| Communities~GDP~ Gross Domestic Product~GP~ General Practitioner~
68 III, 10. 5. 3| Survey~GDP~Gross Domestic Product~HSWA~Health and Safety at
69 IV, 11. 3. 2| reasonable’ price for the product based on balancing affordability
70 IV, 11. 3. 2| cost of a more expensive product. Evidence suggests, however,
71 IV, 11. 3. 2| always clear. In Finland a product’s price and reimbursement
72 IV, 11. 3. 2| least-cost multi-sourced product. However, this policy is
73 IV, 12.Acr | Administration~GNP~Gross National Product~ICH~International Conference
74 IV, 12. 1 | why they will not let a product lawfully marketed in other
75 IV, 12. 2 | products;~regulation of tobacco product disclosures;~packaging and
76 IV, 12. 2 | advertising to description of the product without any of the messages
77 IV, 12. 2 | provides information about a product, its effects and the industry
78 IV, 12. 10 | measurement methods, labelling, product descriptions etc. for tobacco
79 IV, 12. 10 | information activities and a product development effort from
80 IV, 12. 10 | Foundation for comparative product testing (Stiftung Warentest,
81 IV, 12. 10 | complementary procedural rules.~Product responsibility is regarded
82 IV, 12. 10 | related to different products/product groups~ ~Domain of objective
